Clinical trials: Cancer, Carcinoma
Breast Neoplasms
Delphinus SoftVue Prospective Case Collection - ARM 2
The SoftVue™ is a whole breast ultrasound system with an automated scanning curvilinear ring-array transducer that employs UST. It is currently cleared under FDA 510(k) K123209 and K142517 for use as both a B-mode ultrasonic…
- Trial name
- SV PCC ARM2 (NCT02977247)
- Testing
- Non-Interventional, Automated Whole Breast Ultrasound
- Where
- 10 sites in United States
- Volunteers
- 1,150 people
- Sponsor
- Delphinus Medical Technologies, Inc.
Non-Small Cell Lung Cancer
Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib for Inoperable Stage III Non-Small Cell Lung Cancer
Sorafenib has demonstrated in vivo anti-tumor efficacy. This trial will evaluate the safety and preliminary efficacy of sorafenib following chemoradiation in locally advanced NSCLC.
- Trial name
- NCT00417248
- Testing
- Cisplatin, Etoposide, Radiotherapy
- Where
- 8 sites in United States
- Volunteers
- 8 people
- Sponsor
- Nasser Hanna, M.D.
Hepatocellular Carcinoma, Biliary Tract Cancer
Extracellular RNA Markers of Liver Disease and Cancer
The study will examine and evaluate the use of extracellular RNA in blood as markers for the diagnosis of liver disease or cancer, and as markers for prediction of response to treatment or recurrence of cancer after surgery
- Conditions
- Hepatocellular Carcinoma, Biliary Tract Cancer, Cirrhosis, Liver Diseases
- Trial name
- NCT02908048
- Testing
- Blood samples
- Where
- 4 sites in United States
- Volunteers
- 1,865 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Cervical Cancer, Ovarian Clear Cell Carcinoma
Asian Multicenter Prospective Study of ctDNA Sequencing
This study is a genetic analysis of aberrations in circulating tumor DNA (ctDNA) in patients in Asian countries. This study protocol is divided into parts describing several subanalyses that differ in terms of cancer types…
- Conditions
- Cervical Cancer, Ovarian Clear Cell Carcinoma, Nasopharyngeal Carcinoma, Ovarian Cancer
- Trial name
- A-TRAIN (NCT05099978)
- Testing
- NGS analysis of ctDNA
- Where
- 19 sites in Japan, Malaysia and 6 more
- Volunteers
- 506 people
- Sponsor
- National Cancer Center, Japan
Non Small Cell Lung Cancer
Autologous Tumor DRibble Vaccine in Patients With Non-Small Cell Lung Cancer
This is a pilot single institution study of DRibble vaccination + GM-CSF in patients with stage IIIB or IV NSCLC who have undergone 0-1 chemotherapy regimens for metastatic disease.
- Trial name
- DRibble (NCT00850785)
- Testing
- DRibble vaccine
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Providence Health & Services
NSCLC, Stage I, NSCLC, Stage II
The Role of Microbiota on the Development of Lung Cancer
Relationship between human microbiota and epidemiology of lung cancer
- Conditions
- NSCLC, Stage I, NSCLC, Stage II, NSCLC, Stage III, NSCLC Stage IV
- Trial name
- NCT03454685
- Testing
- without intervention type
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Xiaorong Dong
Breast Cancer, Breast Cancer Female
Partial Chest Wall Radiation Therapy After Surgery for Lymph Node Negative Breast Cancer
The standard treatment for breast cancer when cancer cells were found near or within the margins of the tissue that is removed during breast surgery, is radiation of the entire chest wall.
- Conditions
- Breast Cancer, Breast Cancer Female, DCIS, Stage II Breast Cancer
- Trial name
- NCT05436808
- Testing
- Partial Chest Wall Radiation Therapy
- Where
- United States
- Sponsor
- Stony Brook University
Carcinoid Heart Disease
Development and Progression of Carcinoid Heart Disease in a Cohort of Adult Patients With Neuroendocrine Tumors
Carcinoid Heart Disease (CHD) is a rare form of heart disease, occurring in over 50% of the patients with carcinoid syndrome. Pathophysiology, prognostic factors of development of Carcinoid Heart Disease and progression of…
- Trial name
- CRUSOE-NETs (NCT03498040)
- Testing
- Study of the occurrence of Carcinoid Heart Disease
- Where
- 19 sites in France
- Volunteers
- 670 people
- Sponsor
- Hospices Civils de Lyon
Small Cell Lung Cancer
Bevacizumab in Extensive Small Cell Lung Cancer
Despite the fact that a substantial response rate may be obtained in small-cell lung cancers (using double-drug chemotherapy: cisplatin-etoposide, PE), a cure remains an exception.
- Trial name
- CPC (NCT00930891)
- Testing
- Standard Chemotherapy (PCDE or PE), Experimental Treatment (PCDE or PE + bevacizumab), Prerandomization Chemotherapy (PCDE or PE)
- Where
- 60 sites in France
- Volunteers
- 143 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
Breast Carcinoma
A Radiotracer ([18F]FluorThanatrace) by PET/CT for the Imaging of Breast Cancer
This phase II trial tests whether [18F]FluorThanatrace by positron emission tomography (PET)/computed tomography (CT) can improve imaging techniques in patients with breast cancer undergoing a standard of care biopsy or surgery.
- Trial name
- NCT05226663
- Testing
- Computed Tomography, Fluorine F 18 Fluorthanatrace, Positron Emission Tomography
- Where
- 3 sites in United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Oesophageal Squamous Cell Carcinoma, Oesophageal Cancer
Volatile Organic Compounds as Breath Biomarkers in Squamous Oesophageal Neoplasms
Oesophageal Squamous Cell Carcinoma (OSCC) is a cancer of the food pipe that affects around 2000 patients in the UK every year. It is often detected at an advanced stage, resulting in poor survival (5-year survival less than…
- Trial name
- ViSON (NCT06169163)
- Testing
- Exhaled breath sampling
- Where
- 13 sites in United Kingdom
- Volunteers
- 518 people
- Sponsor
- Imperial College London
Non Small Cell Lung Cancer
Efficacy of Re-challenge With Immune-Checkpoints Inhibitors in Advanced Non-Small-Cell Lung Cancer Patients: a Retrospective Observational Study
This is a multicentre, retrospective, national observational study aiming to describe clinical outcomes of advanced NSCLC patients that performed an ICP re-challenge during their history of disease.
- Trial name
- RE-CHALLENGE (NCT04069663)
- Testing
- No interventional study
- Where
- France
- Volunteers
- 144 people
- Sponsor
- University Hospital, Grenoble
High-Risk Cancer, Locally Advanced Breast Cancer
Three Fraction Radiation to Induce Immuno-Oncologic Response
Patients with high risk breast cancers (any locally advanced breast cancer patient defined as Stages IIB-III [excluding inflammatory breast cancer] with stage IIA being eligible for triple negative and HER2-positive breast…
- Trial name
- TRIO (NCT03978663)
- Testing
- Neoadjuvant radiotherapy
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
NSCLC Stage IIIB, Concomitant Radiochemotherapy
Chemoradiotherapy of NSCLC Stage IIIB
To evaluate the best timing of the concomitant chemoradiotherapy among patients with NSCLC stage III not resectable treated by concomitant chemo-radiotherapy, either preceded by a induction chemotherapy, or followed by a…
- Trial name
- NCT00198432
- Testing
- Paclitaxel, vinorelbine, cisplatin
- Where
- France
- Volunteers
- 130 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
Lung Cancer
Laboratory Study Using Samples From Patients With Non-Small Cell Lung Cancer Treated on Clinical Trial CASE-2507
RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and RNA and identify biomarkers related to cancer.
- Trial name
- NCT00907699
- Testing
- DNA analysis, RNA analysis, fluorescence in situ hybridization
- Sponsor
- Case Comprehensive Cancer Center
Hepatocellular Carcinoma
Sorafenib or Lenvatinib Plus HAIC of 130 mg/m² Oxaliplatin, and 5-fu vs Sorafenib or Lenvatinib Plus HAIC of 85mg/m² Oxaliplatin, and 5-fu for Unresectable Advanced HCC: a Randomised Phase 3 Trial
A randomized trial showed that sorafenib plus hepatic artery infusion of 85mg/m² oxaliplatin, leucovorin and fluorouracil is more effective than sorafenib in advanced hepatocellular carcinoma.
- Trial name
- NCT04687163
- Testing
- HAIC of 130 mg/m² Oxaliplatin, and 5-fu, HAIC of 85 mg/m² Oxaliplatin, and 5-fu, TKI
- Where
- 3 sites in China
- Volunteers
- 400 people
- Sponsor
- Sun Yat-sen University
Liver and Intrahepatic Biliary Tract Cancer, Recurrent Extrahepatic Bile Duct Cancer
Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By Surgery
This phase II trial is studying how well selumetinib works in treating patients with biliary cancer that cannot be removed by surgery.
- Conditions
- Liver and Intrahepatic Biliary Tract Cancer, Recurrent Extrahepatic Bile Duct Cancer, Unresectable Extrahepatic Bile Duct Cancer
- Trial name
- NCT00553332
- Testing
- selumetinib, laboratory biomarker analysis
- Where
- 7 sites in United States
- Volunteers
- 29 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Neoplasms, Metastases, Neoplasm
Study of Erbitux (Cetuximab) in Patients With Metastatic Colorectal Carcinoma
This is a phase II, multicenter, target enrollment of 250 evaluable patients, open-label study of cetuximab in patients with refractory, metastatic colorectal carcinoma.
- Trial name
- NCT00044863
- Testing
- Erbitux (Cetuximab)
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Eli Lilly and Company
Small Cell Lung Cancer and Other Solid Tumors
APG-1252 in Patients With SCLC or Advanced Solid Tumors
APG-1252 is a highly potent Bcl-2 family protein inhibitor, a promising drug candidate which shown high binding affinities to Bcl-2, Bcl-xL and Bcl-w.
- Trial name
- NCT03387332
- Testing
- APG-1252
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Ascentage Pharma Group Inc.
Bladder Cancer, Urothelial Carcinoma
Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)
This study aims to demonstrate that home instillation of UGN-102 is a feasible alternative to instillation in a clinical setting, which might mitigate patient challenges (logistical, expense, and comfort) when receiving treatment…
- Conditions
- Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
- Trial name
- NCT05136898
- Testing
- UGN-102
- Where
- 5 sites in United States
- Volunteers
- 8 people
- Sponsor
- UroGen Pharma Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.